TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA(A) receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia

GABAergic drugs are of interest for the treatment of anxiety, depression, bipolar disorder, pain, cognitive impairment associated with schizophrenia (CIAS), and other neuropsychiatric disorders. Some evidence suggests that TPA-023, (7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajagopal, Lakshmi, Huang, Mei, Michael, Eric, Kwon, Sunoh, Meltzer, Herbert Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180114/
https://www.ncbi.nlm.nih.gov/pubmed/30093697
http://dx.doi.org/10.1038/s41386-018-0160-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180114/
https://www.ncbi.nlm.nih.gov/pubmed/30093697
http://dx.doi.org/10.1038/s41386-018-0160-3

Ejemplares similares